Short Interest in Immatics (NASDAQ:IMTXW) Grows By 48.3%

Immatics (NASDAQ:IMTXW) was the recipient of a significant growth in short interest in February. As of February 28th, there was short interest totalling 78,300 shares, a growth of 48.3% from the February 13th total of 52,800 shares. Based on an average trading volume of 26,100 shares, the short-interest ratio is currently 3.0 days.

Immatics Price Performance

Shares of IMTXW traded up $0.02 during midday trading on Monday, hitting $0.04. The company had a trading volume of 21,915 shares, compared to its average volume of 23,839. Immatics has a 52 week low of $0.02 and a 52 week high of $4.00. The company’s 50 day moving average price is $0.05 and its 200 day moving average price is $0.82.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.